Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 14/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 9/20 | 0.55 |
| ▸ | SIRT3 | Q9NTG7 | 6/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 1/20 | 0.54 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5275326 | 0.86 | SIRT2 (0.54) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL14396102 | 0.86 | SIRT2 (0.58) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL30047061 | 0.86 | SIRT2 (0.58) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL29179927 | 0.86 | SIRT2 (0.58) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL5973119 | 0.84 | CTSL (0.58) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL29144124 | 0.84 | CTSL (0.58) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL14561268 | 0.84 | ATM (0.56) | CTSLCTSSCTSK | |
| SCHEMBL5492475 | 0.83 | SIRT2 (0.52) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL4787188 | 0.82 | SIRT2 (0.76) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL31191871 | 0.82 | SIRT2 (0.57) | SIRT2SIRT1SIRT3CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1287006-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2007-10-24 | — | — | EP | disclosed |
| US-7138547-B2 | Antitumoral compounds | PHARMA MAR, S.A. | 2006-11-21 | — | — | US | disclosed |
| US-20040048834-A1 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048834-A1 | Antitumoral compounds | HCCS, MSR1, SUCNR1 | SIRT2 1778/4885SIRT1 2697/4885SIRT3 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.